Sublingual immuno recommended to improve the prevention of influenza A H1N1.
Specialists advised how to prepare for this winter.
- Use associated with the flu vaccine boosted by 60% the protective effect of the vaccine and 50% reduced recurrent infections
- Argentina was one of the countries most affected by the pandemic. In 2009 there were more than 1.4 million cases of influenza, both A and seasonal.
Buenos Aires, May 2010 .- The H1N1 influenza pandemic that swept the world during 2009 was particularly severe in Argentina, with a high number of cases and a higher mortality than in other countries. That is why this year are taking extreme measures to prevent: in addition to specific influenza vaccine, some experts recommend a sublingual immunostimulant that enhances the immune response to the aggression of the virus.
This compound, widely used in Europe, was shown to improve influenza vaccine efficacy, and prevent respiratory infections significantly more common. Dr. Jorge San Juan, head of the Department of Intensive Care Patient Critical Infectious Infectious Diseases Hospital "Francisco J. Muñiz ", said:" Clinical research has shown that the use of immune-associated sublingual flu vaccine boosted by 60% the protective effect of the vaccine reduced by 50% of recurrences compared to isolated use of the vaccine and decreased 60% the need for antibiotics. "
The immunostimulating sublingual stimulates a better immune response through two distinct mechanisms: first, it reinforces the production of NK cells, natural killer, fighting a virus-infected cells, on the other, produces antibodies against bacteria producing 8 78 % of respiratory infections. It can be administered to adults and children two years of age belonging to risk groups and to anyone who wants to prevent respiratory diseases, with an outline of three months of treatment, the rate of one tablet daily for ten days, rest 20 days and restarted the scheme. It has a good safety profile, and there are no reported undesirable side effects associated with their use.
Belonging to risk groups of children 6-23 months, pregnant women, those over 64 years, health professionals, people with heart or lung disease, chronic renal failure, diabetes or asthma and immunosuppressed (cancer, HIV and others), that make in total just over 12 million people in Argentina.
Dr. Carlos Luna, Chief of Pulmonary Critical Pulmonary Division of the Hospital de Clinicas "José de San Martín", noted that "among the main measures of prevention, we must have the vaccination schedule to date, maintain hygienic living habits healthy, and consult with your doctor about the convenience of oral immunostimulants.
Finally, Dr. Ana Balanzat, chief of pediatric pulmonology at the Hospital de Clinicas "José de San Martín", advised hygiene measures that tend to avoid infection: wash your hands (with water and soap or alcohol gel) avoid meetings with sick people or where people conglomerate, no smoking or remain in environments contaminated by smoke snuff, retreat at the first signs of a cold, cough and sneeze into the inside of the elbow, among others. "
One trial in patients older than 18 years showed a decrease of 83% of respiratory infections in the respiratory tract (both viral and bacterial) compared to the placebo group, showing that among those who received the immunostimulant, 79% did not suffer any respiratory infectious episode , versus 4% free of infection in the control group.
Respiratory Diseases in Argentina
Disease No. of cases 2009 *
Influenza (flu) 1.4 million
220 000 Pneumonia
Bronchiolitis 230 000
* Ministry of Health of The Nation. Year 2009
Another study, conducted in children with recurrent respiratory infections showed a significant reduction of respiratory infections (viral and bacterial): 68% of those receiving medication remained free of infection, versus 37% in children to who were given other immunostimulant. The duration of the episodes and antibiotic use was reduced by half in the group treated with sublingual immunostimulant.
Dr. Eduardo Lopez, head of the Department of Medicine, Hospital de Niños "Ricardo Gutiérrez", explained that in 2009 "there were 1.4 million cases of avian influenza or states, 220 000 230 000 pneumonia and bronchiolitis, which gives a true parameter of the high incidence of these diseases, which can become very aggressive when they affect the most vulnerable people, making up the so called "risk groups". " It is estimated that every year in the country 50 000 people for respiratory diseases.
Fragments that immunize
The immunostimulating sublingual (Ismigen ®, Merck Serono), contains a lysate (pieces) of 48 billion bacteria belonging to the species most often attack the airways, causing 78% of respiratory infections. These are: Staphylococcus aureus, Streptococcus pyogenes, Streptococcus viridans, Klebsiella pneumoniae, Klebsiella ozaenae, Haemophilus influenzae type B, Neisseria catarrhalis and Diplococcus pneumoniae. The lysate stimulates the immune system in general, increasing its capacity to respond to the attacks of bacteria, viruses and other microorganisms.
About Merck Serono
Merck Serono is the division for prescription pharmaceuticals of Merck, a global pharmaceutical and chemical group. With headquarters in Darmstadt, Germany, Merck Serono discovers, develops and produces and commercializes innovative molecules and biopharmaceuticals to meet the clinical needs of patients waiting for solutions. Its North American business unit operates in the United States and Canada under the name EMD Serono.
Merck Serono has leading biotechnology therapeutic branches that help cancer patients with multiple sclerosis, infertility, endocrine and cardiometabolic disorders.
With an annual investment in R & D of approximately 1,000 million euros, Merck Serono is committed to increasing its business in areas specific therapeutic including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas that emerge from research and development in autoimmune and inflammatory diseases.
Merck is a global pharmaceutical and chemical company with a history that began in 1668 and whose future is up to 32 458 employees in 59 countries. The company's success is characterized by innovations from initiatives of its employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds approximately 70% of the shares and the remaining 30% is held by independent shareholders. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has since became an independent company.